Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, and improvements ...

Both primary endpoints were met. Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients ... ejection fraction (HFpEF), it sharply cuts the risk of dying from a cardiovascular (CV) event or seeing ...

Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

(RTTNews) - Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in ...

Sold as Zepbound and Mounjaro, the medication reduced the likelihood of hospitalization and death by nearly 40 percent in a new study. Tirzepatide lowered the risk of heart failure–related ...